gene-therapy is the sole category represented across all 1 tracked stories. Dr. Eric Leire is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Dr. Manlio Vinciguerra, all published on August 8, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Dr. Manlio Vinciguerra
gene-therapy is the sole category represented across all 1 tracked stories. Dr. Eric Leire is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Dr. Manlio Vinciguerra, all published on August 8, 2026. Each carries 2 original sources on average.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Dr. Manlio Vinciguerra. Shared-story counts are live from our verified record — not editorial picks.
Genflow's centenarian-derived SIRT6 variant (N308K/A313S) continues to build IP protection, with a new US publication covering NAFLD/NASH and expansion into muscular diseases, underscoring the variant's pleiotropic potential in longevity and age-related conditions.